StockData
Iovance Biotherapeutics, Inc. logo

Iovance Biotherapeutics, Inc. (IOVA) stock

IOVANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3087% above fair value
$7.53−0.02 (-0.26%)

Close on Nov 17, 2026Market cap $3.41BP/E –Yield –

Iovance Biotherapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Iovance Biotherapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $267.72M, down 8.3% year over year. For fiscal 2025 it was $300.27M, up 8.7% from the year before. Over ten years it grew 34.5% a year on average. The highest annual figure on record is $333.19M in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$300.27M+8.7%
FY2024Dec 31, 2024$276.23M-17.1%
FY2023Dec 31, 2023$333.19M+13.0%
FY2022Dec 31, 2022$294.78M+13.8%
FY2021Dec 31, 2021$259.04M+28.4%
FY2020Dec 31, 2020$201.73M+21.5%
FY2019Dec 31, 2019$166.02M+66.3%
FY2018Dec 31, 2018$99.83M+39.4%
FY2017Dec 31, 2017$71.62M+165.8%
FY2016Dec 31, 2016$26.94M+74.1%
FY2015Dec 31, 2015$15.47M+301.9%
FY2014Dec 31, 2014$3.85M+78.7%
FY2013Dec 31, 2013$2.15M+30.1%
FY2012Dec 31, 2012$1.66M-5.7%
FY2011Dec 31, 2011$1.76M+923.7%
FY2010Dec 31, 2010$171.48K–
FY2009Dec 31, 2009$0–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$58.85M-24.5%
Q1 FY2026Mar 31, 2026$62.49M-17.7%
Q4 FY2025Dec 31, 2025$71.20M+0.3%
Q3 FY2025Sep 30, 2025$75.17M+12.1%
Q2 FY2025Jun 30, 2025$77.93M+25.5%
Q1 FY2025Mar 31, 2025$75.97M-4.8%
Q4 FY2024Dec 31, 2024$71.01M-7.3%
Q3 FY2024Sep 30, 2024$67.04M-23.4%
Q2 FY2024Jun 30, 2024$62.08M-28.1%
Q1 FY2024Mar 31, 2024$79.78M-3.6%
Q4 FY2023Dec 31, 2023$76.59M-4.9%
Q3 FY2023Sep 30, 2023$87.53M+20.7%
Q2 FY2023Jun 30, 2023$86.35M+17.6%
Q1 FY2023Mar 31, 2023$82.73M+21.1%
Q4 FY2022Dec 31, 2022$80.57M+6.6%
Q3 FY2022Sep 30, 2022$72.50M+10.9%
Q2 FY2022Jun 30, 2022$73.41M+18.2%
Q1 FY2022Mar 31, 2022$68.30M+22.1%
Q4 FY2021Dec 31, 2021$75.62M+44.2%
Q3 FY2021Sep 30, 2021$65.36M+51.8%
Q2 FY2021Jun 30, 2021$62.12M+26.1%
Q1 FY2021Mar 31, 2021$55.95M-1.8%
Q4 FY2020Dec 31, 2020$52.45M-3.3%
Q3 FY2020Sep 30, 2020$43.05M+3.5%
Q2 FY2020Jun 30, 2020$49.27M+25.4%
Q1 FY2020Mar 31, 2020$56.95M+84.3%
Q4 FY2019Dec 31, 2019$54.24M+97.8%
Q3 FY2019Sep 30, 2019$41.58M+48.8%
Q2 FY2019Jun 30, 2019$39.30M+60.1%
Q1 FY2019Mar 31, 2019$30.91M+55.2%
Q4 FY2018Dec 31, 2018$27.42M+32.5%
Q3 FY2018Sep 30, 2018$27.95M+67.6%
Q2 FY2018Jun 30, 2018$24.55M+31.7%
Q1 FY2018Mar 31, 2018$19.91M+27.7%
Q4 FY2017Dec 31, 2017$20.70M+112.5%
Q3 FY2017Sep 30, 2017$16.68M+96.7%
Q2 FY2017Jun 30, 2017$18.65M–
Q1 FY2017Mar 31, 2017$15.59M–
Q4 FY2016Dec 31, 2016$9.74M–
Q3 FY2016Sep 30, 2016$8.48M–

More Iovance Biotherapeutics figures

See a number that looks wrong?